Document Detail


S-propargyl-cysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway.
MedLine Citation:
PMID:  19546814     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In this study, we determined the cardioprotective effects of S-propargyl-cysteine (SPRC), a structural analog of S-allylcysteine (SAC), using in vivo models of acute myocardial infarction (MI) and in vitro hypoxic cardiomyocytes models. MI was created in rats by ligating the left anterior descending coronary artery. Plasma enzymes levels and cystathionine-gamma-lyase (CSE) activities were determined. Primary cultures of newborn rats' cardiomyocytes were injured by hypoxia for 6 h. Cell viabilities were measured with the thiazolyl blue assay. RT-PCR and western blot analysis revealed the expression of CSE in both models. The protective effects of SPRC were associated with an observed reduction in infarct size (20.8 +/- 2.4% vs. 36.0 +/- 1.3%), decreased plasma enzymes levels and reduced malondialdehyde levels when compared to the MI vehicle group (P < 0.05); cardiac function was also improved. SPRC increased CSE activity and plasma H2S concentration by 1.6-fold and 1.3-fold, respectively, in MI rats. Decreased cell viability (64.5 +/- 5.4%) in hypoxic cardiomyocytes could be rescued with use of SPRC (81.0 +/- 3.1%). Similarly, mRNA and protein expression of CSE were upregulated in the SPRC group. Treatment with the CSE inhibitor propargylglycine abolished the protective effects of SPRC. Our study provides novel evidence that SPRC is protective in myocardial infarctions via a H2S-related pathway.
Authors:
Qian Wang; Hong-Rui Liu; Qing Mu; Peter Rose; Yi Zhun Zhu
Related Documents :
24062184 - Pseudo-postpacing interval of diastolic potential after entrainment pacing of remote by...
3083444 - Temporal discrepancies between low and high frequency vibrations of the second heart so...
23804774 - Late arrhythmias following fontan surgery.
16966244 - The modern mythology of the left-handedness of alexander the great.
8615484 - The effects of alpha 2-adrenergic stimulation with mivazerol on myocardial blood flow a...
8493404 - Cardiac arrest: prognostic factors and outcome at one year.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  54     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-08-20     Completed Date:  2009-12-02     Revised Date:  2011-03-14    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  139-46     Citation Subset:  IM    
Affiliation:
Department of Pharmacology, School of Pharmacy and Institute of Biomedical Sciences, Fudan University, Shanghai, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Animals, Newborn
Cell Hypoxia
Cell Survival / drug effects
Cystathionine gamma-Lyase / drug effects,  genetics,  metabolism
Cysteine / analogs & derivatives*,  pharmacology*
Disease Models, Animal
Hydrogen Sulfide / metabolism*
Male
Myocardial Infarction / physiopathology,  prevention & control*
Myocardial Ischemia / physiopathology,  prevention & control*
Myocytes, Cardiac / drug effects,  pathology
Rats
Rats, Sprague-Dawley
Up-Regulation / drug effects
Chemical
Reg. No./Substance:
0/S-propargylcysteine; 52-90-4/Cysteine; 7783-06-4/Hydrogen Sulfide; EC 4.4.1.1/Cystathionine gamma-Lyase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Time Trends and Regional Differences in the Prevalence of HIV Infection Among Women Attending Antena...
Next Document:  TRC4186, a Novel AGE-breaker, Improves Diabetic Cardiomyopathy and Nephropathy in Ob-ZSF1 Model of T...